Search
for
Sort by
Research 331–360 of 1000+
- Reply to: “Tofacitinib for the treatment of severe alopecia areata and variants”
- Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
- Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
- A 9-month-old infant with severe scalp dermatosis
- Visual Diagnosis: An Adolescent Male With Severe Facial Swelling and Scalp Infection
- Clinical analysis of 83 cases of severe alopecia areata
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- 3D bioprinting of integral ADSCs-NO hydrogel scaffolds to promote severe burn wound healing
- Zinc deficiency associated with hypothyroidism: An overlooked cause of severe alopecia
- Early Onset of Androgenetic Alopecia Associated With Early Severe Coronary Heart Disease: A Population-Based, Case-Control Study
- Immune mechanisms associated with sex-based differences in severe COVID-19 clinical outcomes
- Two-year follow-up of two patients after severe thallium intoxication
- Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series
- A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
- Interest of High-Dose Pulse Corticosteroid Therapy Combined with Methotrexate for Severe Alopecia Areata: A Retrospective Case Series
- A trial of 1% minoxidil used topically for severe alopecia areata
- Effect of minoxidil on blood pressure and hemodynamics in severe hypertension
- The effect of oral cyclosporine in the treatment of severe alopecia areata
- Combined oral pulse and topical corticosteroid therapy for severe alopecia areata in children: a long-term follow-up study
- Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS)
- A trial of 1% minoxidil used topically for severe alopecia areata.
- Breakdown of Immune Tolerance in AIRE-Deficient Rats Induces a Severe Autoimmune Polyendocrinopathy–Candidiasis–Ectodermal Dystrophy–like Autoimmune Disease
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial
- Testosterone protects female embryonic heart H9c2 cells against severe metabolic stress by activating estrogen receptors and up-regulating IES SUR2B
- Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- High-dose steroid pulse therapy for the treatment of severe alopecia areata.
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Sequential high‐ and low‐dose systemic corticosteroid therapy for severe childhood alopecia areata